MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, is scheduled to report 24-week data from its ARGO trial on March 10, 2024.
ARGO is a global phase II trial of the company's lead drug candidate Sonelokimab in active psoriatic arthritis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com